<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Parasit Vectors</journal-id><journal-id journal-id-type="iso-abbrev">Parasit Vectors</journal-id><journal-title-group><journal-title>Parasites &#x00026; Vectors</journal-title></journal-title-group><issn pub-type="epub">1756-3305</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26911244</article-id><article-id pub-id-type="pmc">4765226</article-id><article-id pub-id-type="publisher-id">1376</article-id><article-id pub-id-type="doi">10.1186/s13071-016-1376-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Comparative speed of kill of oral treatments with Simparica<sup>TM</sup>(sarolaner) and Bravecto&#x000ae;(fluralaner) against induced infestations of <italic>Rhipicephalus sanguineus</italic> on dogs</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Becskei</surname><given-names>Csilla</given-names></name><address><email>csilla.becskei@zoetis.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Geurden</surname><given-names>Thomas</given-names></name><address><email>thomas.geurden@zoetis.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Liebenberg</surname><given-names>Julian</given-names></name><address><email>julian.liebenberg@clinvet.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Cuppens</surname><given-names>Otto</given-names></name><address><email>otto.cuppens@zoetis.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Mahabir</surname><given-names>Sean P.</given-names></name><address><email>sean.mahabir@zoetis.com</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Six</surname><given-names>Robert H.</given-names></name><address><email>robert.six@zoetis.com</email></address><xref ref-type="aff" rid="Aff3"/></contrib><aff id="Aff1"><label/>Zoetis, Veterinary Medicine Research and Development, Mercuriusstraat 20, B-1930 Zaventem, Belgium </aff><aff id="Aff2"><label/>ClinVet International (pty) Ltd, Uitsigweg, Bainsvlei, 9338 Bloemfontein Republic of South Africa </aff><aff id="Aff3"><label/>Zoetis, Veterinary Medicine Research and Development, 333 Portage St., Kalamazoo, MI 49007 USA </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>2</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>2</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>9</volume><elocation-id>103</elocation-id><history><date date-type="received"><day>18</day><month>12</month><year>2015</year></date><date date-type="accepted"><day>10</day><month>2</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; Becskei et al. 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p><italic>Rhipicephalus sanguineus</italic> is the most widely distributed tick species infesting dogs worldwide, which may cause discomfort to the host and transmit diseases. Acaricides with a rapid and sustained speed of kill are thus important to prevent infestation and to reduce the risk of disease transmission. In this study, the speed of kill of a monthly administered Simparica<sup>TM</sup>(sarolaner) treatment against induced infestations with <italic>R. sanguineus</italic> on dogs was evaluated and compared with a single dose of Bravecto&#x000ae;(fluralaner) for 95&#x000a0;days after the initial treatment.</p></sec><sec><title>Methods</title><p>Twenty four dogs were randomly allocated to treatment and were treated with either placebo or sarolaner (at 2 to 4&#x000a0;mg/kg) on Days 0, 30 and 60 or with fluralaner (at 25 to 56&#x000a0;mg/kg) once on Day 0. Tick counts were performed <italic>in situ</italic> 8 and 12&#x000a0;h and with removal of the ticks 24&#x000a0;h after treatment and subsequent re-infestations on Days 14, 28, 44, 56, 74, 90 and 95. Acaricidal efficacy was determined at each time point relative to the placebo group.</p></sec><sec><title>Results</title><p>Both products significantly reduced live ticks within 8&#x000a0;h after treatment against an existing infestation with <italic>R. sanguineus</italic>, and killed all ticks on all dogs within 24&#x000a0;h. After re-infestation, sarolaner provided &#x02265;98.5&#x000a0;% reduction within 24&#x000a0;h on all days except Days 74 and 95 (<italic>P&#x02009;&#x0003c;</italic>&#x02009;0.0001), compared to fluralaner which provided &#x02265;95.5&#x000a0;% reduction until Day 44. Geometric mean live tick counts for sarolaner were significantly lower (<italic>P&#x02009;&#x02264;</italic>&#x02009;0.0415) at 24&#x000a0;h than those for fluralaner on all days, except on Days 0, 14 and 28 (<italic>P&#x02009;&#x02265;</italic>&#x02009;0.0678). There were no treatment-related adverse reactions observed during the study.</p></sec><sec><title>Conclusions</title><p>When dosed at monthly intervals for 3 consecutive months, Simparica<sup>TM</sup> has a faster and more consistent speed of kill against <italic>R. sanguineus</italic> than a single oral dose of Bravecto&#x000ae; for which efficacy decreased after Day 44.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd><italic>Rhipicephalus sanguineus</italic></kwd><kwd>Sarolaner</kwd><kwd>Simparica<sup>TM</sup></kwd><kwd>Fluralaner</kwd><kwd>Speed of kill</kwd><kwd>Tick</kwd><kwd>Dog</kwd><kwd>Oral</kwd><kwd>Isoxazoline</kwd><kwd>Bravecto&#x000ae;</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p><italic>Rhipicephalus sanguineus,</italic> also known as the kennel tick or brown dog tick<italic>,</italic> has a worldwide distribution in areas with a relatively warm climate and mild winters [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The introduction of <italic>R. sanguineus</italic> in regions with less favorable conditions has been described, mainly through dogs returning from travel in endemic areas [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. As the tick is known to complete the life cycle in-house and as climate and environmental conditions become more suitable [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>], expansion to new distribution areas is anticipated. <italic>Rhipicephalus sanguineus</italic> is prevalent both in rural and urban areas [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR9">9</xref>], and is a known vector for several vector-borne pathogens<italic>,</italic> including <italic>Ehrlichia</italic> spp<italic>., Babesia canis, Hepatozoon canis</italic> and several <italic>Rickettsia</italic> spp. [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. The awareness of and exposure to tick-borne diseases increases and has driven the emphasis on tick control and prevention in recent years. Simparica<sup>TM</sup>(sarolaner) is an oral isoxazoline parasiticide that provides excellent treatment and prevention of ticks, including <italic>R. sanguineus,</italic> for at least 5&#x000a0;weeks after a single oral dose [<xref ref-type="bibr" rid="CR11">11</xref>]. Although the systemically active compounds require the tick to bite to be effective, the isoxazolines are known to act rapidly. A single dose of sarolaner provides adequate efficacy against <italic>Ixodes ricinus, I. scapularis, Dermacentor reticulatus</italic> and <italic>Amblyomma maculatum</italic> within 24&#x000a0;h after treatment or re-infestation for at least 4&#x000a0;weeks [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. The present study aimed to evaluate and compare the speed of kill of a monthly oral dose of sarolaner with a single oral dose of Bravecto&#x000ae; (fluralaner) against an existing infestation and against re-infestations with <italic>R. sanguineus</italic> for a period of 95&#x000a0;days.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Ethical approval</title><p>Study procedures were in accordance with the World Association for the Advancement of Veterinary Parasitology (WAAVP) guidelines for evaluating the efficacy of parasiticides for the treatment, prevention and control of flea and tick infestation on dogs and cats [<xref ref-type="bibr" rid="CR14">14</xref>]. The protocol was reviewed and approved by the Zoetis Ethical Review Board and local Animal Welfare Committee. Masking of the study was assured through the separation of study functions. All personnel conducting observations or animal care or performing infestations and counts were masked to treatment allocation.</p></sec><sec id="Sec4"><title>Animals</title><p>Twenty-four (12 male and 12 female) purpose-bred Beagle and mixed breed dogs from 11&#x000a0;months to 9&#x000a0;years of age and weighing from 9.4 to 22.8&#x000a0;kg were used in the study. Each dog had undergone an adequate wash-out period to ensure that no residual ectoparasiticide efficacy remained from any previous treatment. Dogs were individually housed and they were acclimatized to these conditions for 8&#x000a0;days prior to treatment. Dogs were fed an appropriate maintenance ration of a commercial canine feed for the duration of the study. Water was available <italic>ad libitum</italic>. All dogs were given a physical examination to ensure that they were in good health at enrollment and were suitable for inclusion in the study. General health observations were performed twice daily throughout the study.</p></sec><sec id="Sec5"><title>Design</title><p>The study followed a randomized complete block design. Dogs were ranked according to decreasing pre-treatment tick counts (48&#x000a0;h after infestation on Day-7) into blocks of three animals, and within each block a dog was randomly allocated to one of three treatment groups. There were eight dogs per treatment group.</p></sec><sec id="Sec6"><title>Treatment</title><p>On Days 0, 30 and 60, two groups of dogs each received either a placebo tablet or an appropriate Simparica<sup>TM</sup> chewable tablet to provide label dose (sarolaner at 2 to 4&#x000a0;mg/kg). The third group of dogs received a Bravecto&#x000ae; tablet (per label providing fluralaner at 25 to 56&#x000a0;mg/kg) on Day 0 and placebo tablets on Days 30 and 60. In order to comply with the Bravecto&#x000ae; label requirement, all dogs were fed within 20&#x000a0;min of the treatment administration. The tablet(s) were administered by hand pilling to ensure accurate and complete dosing. Each dog was observed for several minutes after dosing for evidence that the dose was swallowed, and for potential adverse events associated with treatment administration. Dogs were observed approximately two hours after dosing for evidence of emesis.</p></sec><sec id="Sec7"><title>Tick infestation and assessment</title><p>The <italic>R. sanguineus</italic> strain used for infestation was originally isolated from the field in France in 2007. The colony was genetically enriched by the addition of wild-caught ticks from France in 2012. For treatment allocation dogs were infested with ticks on Day -7 and ticks counts were conducted 48&#x000a0;h later. Further tick infestations were performed on Days -2, 14, 28, 42, 56, 74, 90 and 95. Prior to each infestation, the dog was sedated to enhance tick attachment, and 50 (&#x000b1;5) viable unfed adult <italic>R. sanguineus</italic> (1:1 male:female) were directly applied to each animal. Tick counts were conducted at 8, 12 and 24 (&#x000b1;0.5) hours after treatment and each subsequent weekly re-infestation. Ticks were counted <italic>in situ</italic> (thumb counts) at the 8 and 12&#x000a0;h time points by systematic examination of the entire body surface to ensure that any area was examined only once. At the 24&#x000a0;h counts, dogs were examined and then thoroughly combed to count and remove ticks. Each dog was examined for at least 10&#x000a0;min. If ticks were encountered in the last minute, combing was continued in one minute increments until no ticks were encountered.</p></sec><sec id="Sec8"><title>Statistical analysis</title><p>The individual dog was the experimental unit. Data for post-treatment live (free plus attached) tick counts were summarized with arithmetic (AM) and geometric (GM) means by treatment group and timepoint. Tick counts were transformed by the log<sub>e</sub>(count&#x02009;+&#x02009;1) transformation prior to analysis in order to stabilize the variance and normalize the data. Using the PROC MIXED procedure (SAS 9.2, Cary NC), transformed counts were analyzed using a mixed linear model for repeated measures. The fixed effects were treatment, time-point and the treatment by time-point interaction. Random effects included room, block within room, block by treatment interaction within room, and error. Testing was two-sided at the significance level &#x003b1;&#x02009;=&#x02009;0.05. The assessment of acaricidal efficacy was based on the percent reduction in the arithmetic and geometric mean live tick counts relative to placebo [<xref ref-type="bibr" rid="CR15">15</xref>], and was calculated using Abbott&#x02019;s formula:<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \%\ \mathrm{reduction}=100 \times \frac{\mathrm{mean}\ \mathrm{count}\ \left(\mathrm{placebo}\right)\hbox{--}\ \mathrm{mean}\ \mathrm{count}\ \left(\mathrm{treated}\right)}{\mathrm{mean}\ \mathrm{count}\ \left(\mathrm{placebo}\right)} $$\end{document}</tex-math><mml:math id="M2"><mml:mo>%</mml:mo><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">reduction</mml:mi><mml:mo>=</mml:mo><mml:mn>100</mml:mn><mml:mspace width="0.25em"/><mml:mo>&#x000d7;</mml:mo><mml:mspace width="0.25em"/><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">mean</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">count</mml:mi><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mi mathvariant="normal">placebo</mml:mi></mml:mfenced><mml:mo>&#x02013;</mml:mo><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">mean</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">count</mml:mi><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mi mathvariant="normal">treated</mml:mi></mml:mfenced></mml:mrow><mml:mrow><mml:mi mathvariant="normal">mean</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">count</mml:mi><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mi mathvariant="normal">placebo</mml:mi></mml:mfenced></mml:mrow></mml:mfrac></mml:math><graphic xlink:href="13071_2016_1376_Article_Equa.gif" position="anchor"/></alternatives></disp-formula></p></sec></sec><sec id="Sec9"><title>Results</title><p>The results of the tick counts at each time-point are provided in Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, <xref rid="Tab2" ref-type="table">2</xref> and <xref rid="Tab3" ref-type="table">3</xref>, and in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. Placebo-treated dogs maintained adequate tick infestations throughout the study. Both products significantly reduced tick counts within 8&#x000a0;h after the initial treatment (<italic>P&#x02009;&#x0003c;</italic>&#x02009;0.0001) and achieved &#x0003e;90&#x000a0;% efficacy by 12&#x000a0;h against the existing infestation. At 8 and 12&#x000a0;h after subsequent weekly re-infestations both products had a variable speed of kill and efficacy tended to decline towards the end of the treatment period with tick counts for both groups not being significantly different from placebo on Days 58, 74 and 95 (Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Efficacy of sarolaner after three monthly treatments on Days 0, 30 and 60 and after a single oral dose of fluralaner on Day 0 against <italic>Rhipicephalus sanguineus</italic> on dogs 8&#x000a0;h after treatment and re-infestations (AM: arithmetic mean live tick counts; GM: geometric mean live counts)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Treatment</th><th/><th colspan="8">Day of infestation</th></tr><tr><th/><th>0</th><th>14</th><th>28</th><th>44</th><th>58</th><th>74</th><th>90</th><th>95</th></tr></thead><tbody><tr><td rowspan="3">Placebo</td><td>Range</td><td>15 to 34</td><td>15 to 38</td><td>20 to 39</td><td>15 to 37</td><td>12 to 30</td><td>19 to 36</td><td>19 to 28</td><td>21 to 41</td></tr><tr><td>AM</td><td>20.5</td><td>23.8</td><td>32.3</td><td>28.0</td><td>24.3</td><td>28.8</td><td>23.9</td><td>31.8</td></tr><tr><td>GM<sup>d</sup>
</td><td>19.8<sup>a</sup>
</td><td>22.8<sup>a</sup>
</td><td>31.6<sup>a</sup>
</td><td>27.3<sup>a</sup>
</td><td>23.3<sup>a</sup>
</td><td>28.2<sup>a</sup>
</td><td>23.7<sup>a</sup>
</td><td>31.3<sup>a</sup>
</td></tr><tr><td rowspan="6">Sarolaner</td><td>Range</td><td>0 to 33</td><td>11 to 25</td><td>9 to 19</td><td>9 to 23</td><td>11 to 29</td><td>17 to 49</td><td>8 to 20</td><td>21 to 36</td></tr><tr><td>AM</td><td>6.3</td><td>14.5</td><td>14.1</td><td>14.0</td><td>20.0</td><td>31.6</td><td>12.1</td><td>26.8</td></tr><tr><td>AM Efficacy (%)</td><td>69.5</td><td>38.9</td><td>56.2</td><td>50.0</td><td>17.5</td><td>0.0</td><td>49.2</td><td>15.7</td></tr><tr><td>GM<sup>d</sup>
</td><td>2.7<sup>b</sup>
</td><td>14.0<sup>b</sup>
</td><td>13.8<sup>b</sup>
</td><td>13.5<sup>b</sup>
</td><td>19.0<sup>a</sup>
</td><td>30.4<sup>a</sup>
</td><td>11.7<sup>b</sup>
</td><td>26.3<sup>a</sup>
</td></tr><tr><td>GM Efficacy (%)</td><td>86.6</td><td>38.5</td><td>56.3</td><td>50.6</td><td>18.5</td><td>0.0</td><td>50.8</td><td>16.0</td></tr><tr><td>
<italic>P</italic>-value vs. placebo</td><td>&#x0003c;0.0001</td><td>0.0126</td><td>&#x0003c;0.0001</td><td>0.0003</td><td>0.2857</td><td>0.6949</td><td>0.0004</td><td>0.3561</td></tr><tr><td rowspan="7">Fluralaner</td><td>Range</td><td>0 to 10</td><td>9 to 17</td><td>6 to 16</td><td>9 to 24</td><td>14 to 28</td><td>21 to 34</td><td>5 to 23</td><td>21 to 39</td></tr><tr><td>AM</td><td>2.3</td><td>13.3</td><td>10.0</td><td>16.5</td><td>23.0</td><td>26.0</td><td>13.8</td><td>25.4</td></tr><tr><td>AM Efficacy (%)</td><td>89.0</td><td>44.2</td><td>69.0</td><td>41.1</td><td>5.2</td><td>9.6</td><td>42.4</td><td>20.1</td></tr><tr><td>GM<sup>d</sup>
</td><td>1.3<sup>c</sup>
</td><td>13.0<sup>b</sup>
</td><td>9.5<sup>b</sup>
</td><td>15.7<sup>b</sup>
</td><td>22.5<sup>a</sup>
</td><td>25.6<sup>a</sup>
</td><td>12.8<sup>b</sup>
</td><td>24.9<sup>a</sup>
</td></tr><tr><td>GM Efficacy (%)</td><td>93.6</td><td>43.0</td><td>69.9</td><td>42.4</td><td>3.4</td><td>9.3</td><td>46.1</td><td>20.3</td></tr><tr><td>
<italic>P</italic>-value vs. placebo</td><td>&#x0003c;0.0001</td><td>0.0050</td><td>&#x0003c;0.0001</td><td>0.0055</td><td>0.8580</td><td>0.6132</td><td>0.0021</td><td>0.2415</td></tr><tr><td>
<italic>P</italic>-value vs. sarolaner</td><td>0.0433</td><td>0.7638</td><td>0.1461</td><td>0.5413</td><td>0.4936</td><td>0.4822</td><td>0.7219</td><td>0.8301</td></tr></tbody></table><table-wrap-foot><p>
<sup>d</sup>Geometric means within a counting day with the same superscript are not significantly different (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05)</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>Efficacy of sarolaner after three monthly treatments on Days 0, 30 and 60 and after a single oral dose of fluralaner on Day 0 against <italic>Rhipicephalus sanguineus</italic> on dogs 12&#x000a0;h after treatment and re-infestations (AM: arithmetic mean live tick counts; GM: geometric mean live counts)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Treatment</th><th/><th colspan="8">Day of infestation</th></tr><tr><th/><th>0</th><th>14</th><th>28</th><th>44</th><th>58</th><th>74</th><th>90</th><th>95</th></tr></thead><tbody><tr><td rowspan="3">Placebo</td><td>Range</td><td>11 to 35</td><td>17 to 37</td><td>20 to 39</td><td>24 to 37</td><td>13 to 26</td><td>12 to 34</td><td>20 to 26</td><td>20 to 38</td></tr><tr><td>AM</td><td>20.8</td><td>24.1</td><td>31.6</td><td>28.3</td><td>21.4</td><td>26.8</td><td>22.3</td><td>29.1</td></tr><tr><td>GM<sup>d</sup>
</td><td>19.7<sup>a</sup>
</td><td>23.5<sup>a</sup>
</td><td>31.1<sup>a</sup>
</td><td>28.0<sup>a</sup>
</td><td>20.8<sup>a</sup>
</td><td>25.8<sup>a</sup>
</td><td>22.2<sup>a</sup>
</td><td>28.7<sup>a</sup>
</td></tr><tr><td rowspan="6">Sarolaner</td><td>Range</td><td>0 to 11</td><td>2 to 12</td><td>7 to 14</td><td>5 to 14</td><td>9 to 23</td><td>12 to 38</td><td>5 to 22</td><td>20 to 33</td></tr><tr><td>AM</td><td>1.6</td><td>8.0</td><td>10.0</td><td>10.0</td><td>17.0</td><td>26.9</td><td>12.1</td><td>25.5</td></tr><tr><td>AM Efficacy (%)</td><td>92.2</td><td>66.8</td><td>68.4</td><td>64.6</td><td>20.5</td><td>0.0</td><td>45.5</td><td>12.4</td></tr><tr><td>GM<sup>d</sup>
</td><td>0.6<sup>b</sup>
</td><td>7.3<sup>b</sup>
</td><td>9.7<sup>b</sup>
</td><td>9.6<sup>b</sup>
</td><td>16.3<sup>a</sup>
</td><td>25.7<sup>a</sup>
</td><td>11.1<sup>b</sup>
</td><td>25.1<sup>a</sup>
</td></tr><tr><td>GM Efficacy (%)</td><td>96.8</td><td>69.0</td><td>68.7</td><td>65.7</td><td>21.6</td><td>0.3</td><td>49.8</td><td>12.4</td></tr><tr><td>
<italic>P</italic>-value vs. placebo</td><td>&#x0003c;0.0001</td><td>&#x0003c;0.0001</td><td>&#x0003c;0.0001</td><td>&#x0003c;0.0001</td><td>0.2065</td><td>0.9863</td><td>0.0005</td><td>0.4861</td></tr><tr><td rowspan="7">Fluralaner</td><td>Range</td><td>0 to 2</td><td>2 to 11</td><td>3 to 10</td><td>5 to 19</td><td>9 to 24</td><td>19 to 32</td><td>5 to 17</td><td>21 to 29</td></tr><tr><td>AM</td><td>0.4</td><td>5.9</td><td>5.8</td><td>11.0</td><td>16.4</td><td>24.4</td><td>12.8</td><td>24.9</td></tr><tr><td>AM Efficacy (%)</td><td>98.2</td><td>75.6</td><td>81.8</td><td>61.1</td><td>23.4</td><td>8.9</td><td>42.7</td><td>14.6</td></tr><tr><td>GM<sup>d</sup>
</td><td>0.3<sup>b</sup>
</td><td>5.3<sup>b</sup>
</td><td>5.3<sup>c</sup>
</td><td>9.9<sup>b</sup>
</td><td>15.4<sup>a</sup>
</td><td>23.9<sup>a</sup>
</td><td>12.1<sup>b</sup>
</td><td>24.7<sup>a</sup>
</td></tr><tr><td>GM Efficacy (%)</td><td>98.7</td><td>77.5</td><td>83.1</td><td>64.5</td><td>26.1</td><td>7.3</td><td>45.4</td><td>13.7</td></tr><tr><td>
<italic>P</italic>-value vs. placebo</td><td>&#x0003c;0.0001</td><td>&#x0003c;0.0001</td><td>&#x0003c;0.0001</td><td>&#x0003c;0.0001</td><td>0.1267</td><td>0.6959</td><td>0.0027</td><td>0.4485</td></tr><tr><td>
<italic>P</italic>-value vs. sarolaner</td><td>0.2720</td><td>0.2450</td><td>0.0238</td><td>0.8946</td><td>0.8149</td><td>0.7673</td><td>0.7431</td><td>0.9509</td></tr></tbody></table><table-wrap-foot><p>
<sup>d</sup>Geometric means within a counting day with the same superscript are not significantly different (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05)</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>Efficacy of sarolaner after three monthly treatments on Days 0, 30 and 60 and after a single oral dose of fluralaner on Day 0 against <italic>Rhipicephalus sanguineus</italic> on dogs 24&#x000a0;h after treatment and re-infestations (AM: arithmetic mean live tick counts; GM: geometric mean live counts)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Treatment</th><th/><th colspan="8">Day of infestation</th></tr><tr><th/><th>0</th><th>14</th><th>28</th><th>44</th><th>58</th><th>74</th><th>90</th><th>95</th></tr></thead><tbody><tr><td rowspan="3">Placebo</td><td>Range</td><td>14 to 36</td><td>21 to 39</td><td>21 to 39</td><td>21 to 37</td><td>14 to 29</td><td>18 to 36</td><td>22 to 31</td><td>25 to 37</td></tr><tr><td>AM</td><td>23.5</td><td>26.3</td><td>28.8</td><td>28.0</td><td>25.0</td><td>29.0</td><td>25.8</td><td>30.5</td></tr><tr><td>GM<sup>d</sup>
</td><td>22.8<sup>a</sup>
</td><td>25.8<sup>a</sup>
</td><td>28.2<sup>a</sup>
</td><td>27.6<sup>a</sup>
</td><td>24.4<sup>a</sup>
</td><td>28.3<sup>a</sup>
</td><td>25.6<sup>a</sup>
</td><td>30.2<sup>a</sup>
</td></tr><tr><td rowspan="6">Sarolaner</td><td>Range</td><td>0 to 0</td><td>0 to 1</td><td>0 to 1</td><td>0 to 2</td><td>0 to 1</td><td>1 to 11</td><td>0 to 2</td><td>0 to 11</td></tr><tr><td>AM</td><td>0.0</td><td>0.3</td><td>0.1</td><td>0.3</td><td>0.3</td><td>5.3</td><td>0.4</td><td>3.8</td></tr><tr><td>AM Efficacy (%)</td><td>100</td><td>99.0</td><td>99.6</td><td>99.1</td><td>99.0</td><td>81.9</td><td>98.5</td><td>87.7</td></tr><tr><td>GM<sup>d</sup>
</td><td>0.0<sup>b</sup>
</td><td>0.2<sup>b</sup>
</td><td>0.1<sup>b</sup>
</td><td>0.1<sup>c</sup>
</td><td>0.2<sup>c</sup>
</td><td>4.6<sup>c</sup>
</td><td>0.3<sup>c</sup>
</td><td>2.5<sup>c</sup>
</td></tr><tr><td>GM Efficacy (%)</td><td>100</td><td>99.3</td><td>99.7</td><td>99.5</td><td>99.2</td><td>83.8</td><td>99.0</td><td>91.9</td></tr><tr><td>
<italic>P</italic>-value vs. placebo</td><td>&#x0003c;0.0001</td><td>&#x0003c;0.0001</td><td>&#x0003c;0.0001</td><td>&#x0003c;0.0001</td><td>&#x0003c;0.0001</td><td>&#x0003c;0.0001</td><td>&#x0003c;0.0001</td><td>&#x0003c;0.0001</td></tr><tr><td rowspan="7">Fluralaner</td><td>Range</td><td>0 to 0</td><td>0 to 3</td><td>0 to 1</td><td>0 to 5</td><td>0 to 8</td><td>4 to 27</td><td>4 to 20</td><td>2 to 32</td></tr><tr><td>AM</td><td>0.0</td><td>1.1</td><td>0.1</td><td>1.3</td><td>3.1</td><td>16.8</td><td>10.8</td><td>14.8</td></tr><tr><td>AM Efficacy (%)</td><td>100</td><td>95.7</td><td>99.6</td><td>95.5</td><td>87.5</td><td>42.2</td><td>58.3</td><td>51.6</td></tr><tr><td>GM<sup>d</sup>
</td><td>0.0<sup>b</sup>
</td><td>0.8<sup>b</sup>
</td><td>0.1<sup>b</sup>
</td><td>0.9<sup>b</sup>
</td><td>1.6<sup>b</sup>
</td><td>14.8<sup>b</sup>
</td><td>9.1<sup>b</sup>
</td><td>10.8<sup>b</sup>
</td></tr><tr><td>GM Efficacy (%)</td><td>100</td><td>96.8</td><td>99.7</td><td>96.9</td><td>93.5</td><td>47.9</td><td>64.6</td><td>64.3</td></tr><tr><td>
<italic>P</italic>-value vs. placebo</td><td>&#x0003c;0.0001</td><td>&#x0003c;0.0001</td><td>&#x0003c;0.0001</td><td>&#x0003c;0.0001</td><td>&#x0003c;0.0001</td><td>0.0011</td><td>&#x0003c;0.0001</td><td>&#x0003c;0.0001</td></tr><tr><td>
<italic>P</italic>-value vs. sarolaner</td><td>1.0000</td><td>0.0678</td><td>1.0000</td><td>0.0415</td><td>0.0012</td><td>&#x0003c;0.0001</td><td>&#x0003c;0.0001</td><td>&#x0003c;0.0001</td></tr></tbody></table><table-wrap-foot><p>
<sup>d</sup>Geometric means within a counting day with the same superscript are not significantly different (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05)</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><p>Percent efficacy based on geometric mean <italic>Rhipicephalus sanguineus</italic> counts relative to placebo at 24&#x000a0;h after treatment and weekly re-infestation for dogs receiving a monthly oral dose of sarolaner on Days 0, 30 and 60 or a single oral dose of fluralaner on Day 0</p></caption><graphic xlink:href="13071_2016_1376_Fig1_HTML" id="MO1"/></fig></p><p>Twenty-four hours after treatment, no live ticks were found on any sarolaner or fluralaner-treated dog (100&#x000a0;% efficacy; <italic>P&#x02009;&#x0003c;</italic>&#x02009;0.0001 vs placebo; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Twenty-four hours after subsequent re-infestations, the reduction in AM (GM) tick counts for sarolaner was above 98.5&#x000a0;% (99.0&#x000a0;%) for 4&#x000a0;weeks after each monthly treatment, except on Day 74 when efficacy was 81.9&#x000a0;% (83.8&#x000a0;%). GM live tick counts for sarolaner were significantly lower (<italic>P&#x02009;&#x0003c;</italic>&#x02009;0.0001) than placebo on all days. The reduction in AM (GM) tick counts for fluralaner was &#x02265;95.5&#x000a0;% (96.9&#x000a0;%) until Day 44, and ranged from 42.2&#x000a0;% (47.9&#x000a0;%) to 87.5&#x000a0;% (93.5&#x000a0;%) for the remainder of the study period. GM live tick counts for both products were significantly lower (<italic>P&#x02009;&#x02264;</italic>&#x02009;0.0011) than placebo on all days, and significantly fewer (<italic>P&#x02009;&#x02264;</italic>&#x02009;0.0415) live ticks were found on sarolaner-treated dogs compared to fluralaner-treated dogs from Day 44 onwards. There were no treatment-related adverse reactions during the study.</p></sec><sec id="Sec10"><title>Discussion</title><p>Sarolaner significantly reduced <italic>R. sanguineus</italic> tick counts within 8&#x000a0;h after the first treatment on Day 0 and demonstrated a consistently high efficacy within 24&#x000a0;h after 3 monthly treatments. In contrast, the speed of kill of fluralaner was significantly slower from Day 44 onwards. These results are consistent with a previous study in which the speed of kill of fluralaner against <italic>R. sanguineus</italic> and <italic>Dermacentor reticulatus</italic> also decreased in the third month after treatment [<xref ref-type="bibr" rid="CR15">15</xref>]. In the present study, significantly more <italic>R. sanguineus</italic> ticks were found on the fluralaner-treated dogs from Day 44 onwards compared to dogs treated monthly with sarolaner. These results illustrate that the perceived benefit of a longer treatment interval and hence the need for less treatments, needs to be balanced with the potential risk of an unpredictable decline in efficacy at the end of the claimed treatment period. An important benefit of monthly sarolaner administration is that it provides a sustained efficacy against all relevant tick species in dogs [<xref ref-type="bibr" rid="CR11">11</xref>] as well as maintaining a rapid speed of kill for the entire duration of the efficacy claim period against <italic>R. sanguineus</italic> and other tick species (<italic>I. ricinus</italic>, <italic>I. scapularis, D. reticulatus</italic> and <italic>A. maculatum</italic>) [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. As <italic>R. sanguineus</italic> is the vector of a range of tick-borne diseases worldwide, the rapid and consistent speed of kill provided by monthly treatments with sarolaner will be an important aid in the prevention of tick-borne disease transmission.</p></sec><sec id="Sec11"><title>Conclusions</title><p>This study confirmed the consistent acaricidal efficacy of sarolaner against <italic>R. sanguineus</italic> and demonstrated that ticks were killed rapidly during the entire treatment period. Monthly treatment with sarolaner consistently killed more ticks within 24&#x000a0;h than a single dose of fluralaner from 6 to 13&#x000a0;weeks after initial treatment.</p></sec></body><back><fn-group><fn><p><bold>Competing interests</bold></p><p>The study reported here was funded by Zoetis, Florham Park, NJ. CB, TG, OC, SPM, and RHS are current employees of Zoetis. JL was an independent investigator contracted for the study. There were no conflicting interests that could have influenced the conduct and reporting of this study.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>Authors assisted with the study design, study conduct, interpretation of the data and manuscript review. All authors read and approved the final version of the manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors would like to thank Douglas Rugg for his assistance in drafting the manuscript.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uspensky</surname><given-names>I</given-names></name></person-group><article-title>Tick pests and vectors (Acari: <italic>Ixodoidea</italic>) in European towns: Introduction, persistence and management</article-title><source>Ticks Tick Borne Dis</source><year>2014</year><volume>5</volume><fpage>41</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.ttbdis.2013.07.011</pub-id><pub-id pub-id-type="pmid">24183576</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xhaxhiu</surname><given-names>D</given-names></name><name><surname>Kusi</surname><given-names>I</given-names></name><name><surname>Rapti</surname><given-names>D</given-names></name><name><surname>Visser</surname><given-names>M</given-names></name><name><surname>Knaus</surname><given-names>M</given-names></name><name><surname>Lindner</surname><given-names>T</given-names></name><etal/></person-group><article-title>Ectoparasites of dogs and cats in Albania</article-title><source>Parasitol Res</source><year>2009</year><volume>105</volume><fpage>1577</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1007/s00436-009-1591-x</pub-id><pub-id pub-id-type="pmid">19690887</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>S</given-names></name><name><surname>Schreiber</surname><given-names>C</given-names></name><name><surname>Schein</surname><given-names>E</given-names></name><name><surname>Kr&#x000fc;cken</surname><given-names>J</given-names></name><name><surname>Baldermann</surname><given-names>C</given-names></name><name><surname>Pachnicke</surname><given-names>S</given-names></name><etal/></person-group><article-title>Tick infestation and prophylaxis of dogs in northeastern Germany: a prospective study</article-title><source>Ticks Tick Borne Dis</source><year>2014</year><volume>5</volume><fpage>336</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.ttbdis.2013.12.009</pub-id><pub-id pub-id-type="pmid">24629616</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claerebout</surname><given-names>E</given-names></name><name><surname>Losson</surname><given-names>B</given-names></name><name><surname>Cochez</surname><given-names>C</given-names></name><name><surname>Casaert</surname><given-names>S</given-names></name><name><surname>Dalemans</surname><given-names>AC</given-names></name><name><surname>De Cat</surname><given-names>A</given-names></name><etal/></person-group><article-title>Ticks and associated pathogens collected from dogs and cats in Belgium</article-title><source>Parasit Vectors</source><year>2013</year><volume>6</volume><fpage>183</fpage><pub-id pub-id-type="doi">10.1186/1756-3305-6-183</pub-id><pub-id pub-id-type="pmid">23777784</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Featherstone</surname><given-names>C</given-names></name><name><surname>Phipps</surname><given-names>P</given-names></name><name><surname>Pietzsch</surname><given-names>M</given-names></name><name><surname>Hansford</surname><given-names>K</given-names></name><name><surname>Medlock</surname><given-names>J</given-names></name></person-group><article-title>Tick surveillance in the UK</article-title><source>Vet Rec</source><year>2012</year><volume>171</volume><fpage>225</fpage><pub-id pub-id-type="doi">10.1136/vr.e5831</pub-id><pub-id pub-id-type="pmid">22941822</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansford</surname><given-names>KM</given-names></name><name><surname>Pietzsch</surname><given-names>ME</given-names></name><name><surname>Cull</surname><given-names>B</given-names></name><name><surname>Medlock</surname><given-names>JM</given-names></name></person-group><article-title>Importation of <italic>R sanguineus</italic> into the UK via dogs: tickborne diseases</article-title><source>Vet Rec</source><year>2014</year><volume>175</volume><fpage>385</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1136/vr.g6226</pub-id><pub-id pub-id-type="pmid">25324415</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansford</surname><given-names>KM</given-names></name><name><surname>Pietzsch</surname><given-names>M</given-names></name><name><surname>Cull</surname><given-names>B</given-names></name><name><surname>Medlock</surname><given-names>JM</given-names></name></person-group><article-title>Brown dog tick infestation of a home in England</article-title><source>Vet Rec</source><year>2015</year><volume>176</volume><fpage>129</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1136/vr.h496</pub-id><pub-id pub-id-type="pmid">25634925</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beugnet</surname><given-names>F</given-names></name><name><surname>Kolasinski</surname><given-names>M</given-names></name><name><surname>Michelangeli</surname><given-names>PA</given-names></name><name><surname>Vienne</surname><given-names>J</given-names></name><name><surname>Loukos</surname><given-names>H</given-names></name></person-group><article-title>Mathematical modelling of the impact of climatic conditions in France on <italic>Rhipicephalus sanguineus</italic> tick activity and density since 1960</article-title><source>Geospat Health</source><year>2011</year><volume>5</volume><fpage>255</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.4081/gh.2011.178</pub-id><pub-id pub-id-type="pmid">21590676</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancini</surname><given-names>F</given-names></name><name><surname>Di Luca</surname><given-names>M</given-names></name><name><surname>Toma</surname><given-names>L</given-names></name><name><surname>Vescio</surname><given-names>F</given-names></name><name><surname>Bianchi</surname><given-names>R</given-names></name><name><surname>Khoury</surname><given-names>C</given-names></name><etal/></person-group><article-title>Prevalence of tick-borne pathogens in an urban park in Rome, Italy</article-title><source>Ann Agric Environ Med</source><year>2014</year><volume>21</volume><fpage>723</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.5604/12321966.1129922</pub-id><pub-id pub-id-type="pmid">25528909</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>WL</given-names></name><name><surname>Allen</surname><given-names>KE</given-names></name><name><surname>McQuiston</surname><given-names>JH</given-names></name><name><surname>Breitschwerdt</surname><given-names>EB</given-names></name><name><surname>Little</surname><given-names>SE</given-names></name></person-group><article-title>The increasing recognition of rickettsial pathogens in dogs and people</article-title><source>Trends Parasitol</source><year>2010</year><volume>26</volume><fpage>205</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2010.01.007</pub-id><pub-id pub-id-type="pmid">20207197</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Geurden T, Becskei C, Grace S, Strube C, Doherty P, Liebenberg J, Mahabir SP, Slootmans N, Lloyd A, Six RH. Efficacy of a novel oral formulation of sarolaner (Simparica &#x02122;) against four common tick species infesting dogs in Europe. Vet Parasitol, under final review.</mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Six RH, Geurden T, Carter L, Everett WR, McLoughlin A, Mahabir SP, Myers MR, Slootmans N. Knock-down and speed of kill of sarolaner (Simparica<sup>TM</sup>) against induced infestations of three species of ticks (<italic>Amblyomma maculatum, Ixodes scapularis, Ixodes ricinus</italic>). Vet Parasitol, accepted.</mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Becskei C, Geurden T, Erasmus H, Cuppens O, MahabirSP, Six RH. Comparative speed of kill for Simparica<sup>TM</sup> (sarolaner) and Advantix&#x000ae; (imidacloprid&#x02009;+&#x02009;permethrin Spot-on solution) against induced infestations of <italic>Dermacentor reticulatus</italic> on dogs. Parasit Vectors; in press.</mixed-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchiondo</surname><given-names>AA</given-names></name><name><surname>Holdsworth</surname><given-names>PA</given-names></name><name><surname>Fourie</surname><given-names>LJ</given-names></name><name><surname>Rugg</surname><given-names>D</given-names></name><name><surname>Hellmann</surname><given-names>K</given-names></name><name><surname>Snyder</surname><given-names>DE</given-names></name><etal/></person-group><article-title>World Association for the Advancement of Veterinary Parasitology (W.A.A.V.P.) 2nd. ed.: Guidelines for evaluating the efficacy of parasiticides for the treatment, prevention and control of flea and tick infestations on dogs and cats</article-title><source>Vet Parasitol</source><year>2013</year><volume>194</volume><fpage>84</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.vetpar.2013.02.003</pub-id><pub-id pub-id-type="pmid">23741753</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beugnet</surname><given-names>F</given-names></name><name><surname>Liebenberg</surname><given-names>J</given-names></name><name><surname>Halos</surname><given-names>L</given-names></name></person-group><article-title>Comparative efficacy of two oral treatments for dogs containing either afoxolaner or fluralaner against <italic>Rhipicephalus sanguineus sensu lato</italic> and <italic>Dermacentor reticulatus</italic></article-title><source>Vet Parasitol</source><year>2015</year><volume>209</volume><fpage>142</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.vetpar.2015.02.002</pub-id><pub-id pub-id-type="pmid">25716658</pub-id></element-citation></ref></ref-list></back></article>